Neoadjuvant serplulimab with concurrent chemoradiotherapy in resectable esophagogastric junction adenocarcinoma: Phase 2 updated results. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of ...

Feasibility Study for Using Large Language Models to Identify Goals-of-Care Documentation at Scale in Patients With Advanced Cancer A retrospective analysis of 3,626 patients treated with ICIs for ...

Cancer immunotherapy has historically focused on harnessing the ability of T cells to recognize and attack cancer cells. Adaptive immune checkpoint inhibitors (ICIs) unleash tumor-infiltrating ...

A nationwide cohort study in Taiwan found a higher risk of psoriasis in cancer patients treated with immune checkpoint inhibitors compared to other therapies. The study analyzed data from 3,188 ...

Narcolepsy is a rare disorder of central hypersomnolence which is often under-recognised owing to a variable clinical phenotype. Narcolepsy type 1 (NT1) is caused by loss of hypothalamic hypocretin ...

Checkpoint inhibitors have transformed cancer treatment over the past decade, helping hundreds of thousands of patients by ...

ICIs combined with chemotherapy showed higher efficacy than bevacizumab in treating advanced driver gene–negative NS-NSCLC. The study reported improved PFS and OS for patients receiving ICIs compared ...

MIRAMAR, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to ...

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in ...

Please provide your email address to receive an email when new articles are posted on . Current therapies do not prevent the onset of new lesions within a field of cancerization. Immune checkpoint ...